ClinicalTrials.gov
public full text
Public Domain
Tyrosine Kinase 2 (TYK2) for GA and CS
To investigate the role of an oral TYK2 inhibitor for the treatment of patients with moderate to severe sarcoidosis with cutaneous involvement (CSAMI score of 10 or greater) and GA (defined as a BSA involvement of at least 5%), which are difficult to treat.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI#800187
- Direct Inhibition Of Bruton's Tyrosine Kinase By IBtk, A Btk-binding Protein#19607
- Sarcolipin-SERCA uncoupling as a plausible heat source for sustaining fever.#354727
- Mechanism and Immune Function Analysis of SARS-CoV-2 Infection in Hematologic Tumors#1010651
- A Case Controlled Etiologic Study of Sarcoidosis (ACCESS)#910966
Record · ID 851592
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive